While the S&P/ASX 200 Index (ASX: XJO) hasn't provided much of a Santa rally this year, there are a number of ASX-listed shares that are still feeling merry this December.
Taking a look at the data, 20 companies on the ASX with a market capitalisation of more than $250 million have experienced a gain of 15% or greater so far this month.
Today, we'll take a look at three of these companies to see what's driving their high spirits.
These ASX shares have made it onto the good list in December
It's the season for giving, and investors like to receive a pleasant surprise as much as anyone else. Fortunately, the shareholders of the next three companies have been treated to share price gains of more than 15% in December alone.
Best & Less Group Holdings Ltd (ASX: BST)
The first ASX share charging towards Christmas with strong share price appreciation is Best & Less. Since the beginning of the month, shares in the clothing retailer have rallied 15.3%.
The lift comes after the company experienced a steep 27% selloff in its shares from 9 November to 26 November. While the market seemed put off by Best & Less's underwhelming trading update in mid-November, the sentiment has shifted.
Late last month, the company shared its annual general meeting presentation. Positively, those slides contained promising performance for Best & Less online sales. In fact, online sales were reportedly up 33.5% on FY20. Similarweb's traffic overview shows Best & Less website visits at 2.42 million in November, compared to 1.9 million in July.
DGL Group Ltd (ASX: DGL)
The next ASX share climbing down the chimney to make its way onto this list is DGL Group. It has been a solid month so far for the chemical supplies company, rising 18.3% since 1 December.
A shortage of the diesel fuel additive AdBlue could be driving heightened awareness of DGL Group. The company is Australia's largest supplier of the emission-reducing mixture, though supplies are quickly dwindling. Hopefully, an agreement reached between Incitec Pivot Ltd (ASX: IPL) and the federal government should prevent a crisis.
Neuren Pharmaceuticals Ltd (ASX: NEU)
Finally, we've left the biggest gift giver for last — Neuren Pharmaceuticals. This ASX-listed biopharmaceutical share has more than doubled in value since the merry month kicked off. The Neuren Pharmaceutical share price has rewarded its shareholders with a 104% gain.
The exhilarating surge in share price followed the company's announcement of positive phase three clinical trial results. Specifically, Neuren's application of trofinetide to treat young women with Rett syndrome yielded promising data. As a result, the treatment will begin to move through the regulatory process for approval.
